Azienda Ospedaliera Ordine Mauriziano Di Torino — Clinical Trial Site

136 Registered trials

71 Currently recruiting

Organisation

Azienda Ospedaliera Ordine Mauriziano Di Torino

Location

Turin, Italy

Identifier

ORG-100043901

Address

Via Ferdinando Magellano 1, 10128, Italy

Departments

#3607:S.C.D.U. Allergologia e Immunologia Clinica
#4104: S.C.D.U. Oncologia
#8018:S.C.D.U. Ematologia
1517: SCDU Ematologia e Terapie Cellulari
2603: S.C.D.U. Ematologia e Terapie Cellulari
3607; S.C.D.U. Allergologia e Immunologia Clinica Presidio Ospedaliero Unberto I
4045: S.S.D.D.U. Reumatologia Università degli Studi
4114:Unità di Oncologia Ginecologica
A.O. Ordine Mauriziano
Academic Department Gynaecology and Obstetrics
Academic Gynecology Division
Allergology and Clinical immunology
Anesthesia and Intensive Care
Area Medica
Cardiologia
Cardiology
Complex Operative Unit of Gastroenterology - largo Turati 62, 10128 Turin
Complex Operative Unit of Gastroenterology - largo Turati, 62 Turin
Complex Operative Unit of Gastroenterology / largo Turati, 62, 10128 Turin
Department of Clinical and Biological Sciences
Department of Oncology
Dept of Clinical and Biological Sciences
Digestive endoscopy
Dipartimento di Oncologia
Dipartimento di Oncologia Medica
Dipartimento di Scienze Cliniche e Biologiche
Dipartimento di Scienze Cliniche e Biologiche - SCDU EMATOLOGIA
Divisione di Ostetricia e Ginecologia
Gastroenterologia
Gastroenterology Unit
Ginecologia
Ginecologia e Ostetricia
Ginecologia Oncologica
Ginecology
Gynecology and Obstetrics
IT10012: Reumatologia
medical oncology
Medico
N/A
Oncologia
Oncologia Ginecologica
Oncologia medica
Oncology
Oncology Department
Oncology Unit
S.C. Cardiologia
S.C. Cardiololgia
S.C. Endocrinologia, Diabetologia e Malattie del Metabolismo
S.C. Gastroenterologia
S.C. Gastroenterologia - Endoscopia Digestiva
S.C. Gastroenterologia reparto di endoscopia digestiva
S.C. Oculistica
S.C.D.U. Ematologia e Terapie Cellulari
S.C.D.U. Oncologia
S.C.D.U. Ostetricia e Ginecologia
S.S.D.D.U. Reumatologia
SC Endocrinologia
SC Gastroenterologia
SCDU Ematologia e Terapie Cellulari
SCDU Allergologia e Immunologia
SCDU Allergologia e Immunologia Clinica
SCDU Ematologia
SCDU Ematologia e Terapie cellulari
SCDU Ematologia e Terapie Cellulari
SCDU Ematologia, Largo Filippo Turati 62, 10128,Turin, Italy
SCDU Ginecologia e Ostetricia – settore MED 40
SCDU Ginecologia e Ostetricia, Ginecologi Oncologica
SCDU Ginecologia ed Ostetricia
SCDU Hematology
SCDU Immunologia e Allergologia
SCDU Medical Oncology
SCDU Oncologia
SCDU Oncologia Medica
SDCU Allergy and Clinical Immunology
Struttura complessa (SC) Gastroenterolo gia
Struttura Complessa Cardiologia
UO Cardiologia
UOC of Gastroenterology - Largo Turati 62, Turin

Clinical trials at this site (136)

Search interface

Study to treat adult patients with BCR-ABL1+ Chronic Myeloid Leukemia with Asciminib as single agent or in combination with nilotinib:a GIME… Recruiting

2024-512696-12-00 BCR-ABL1+ Chronic Myeloid Leukemia 4 2025-06-24
A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting

2023-509391-42-00 Chron's Disease 11 2025-06-02
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens … Recruiting

2024-517432-21-00 Gynecological Cancers 4 2025-05-30
A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting

2024-516009-22-00 myelodysplastic neoplasms/syndromes (MDS) 5 2025-04-30
A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting

2024-511495-32-00 Chronic Phase Chronic Myeloid Leukemia 5 2025-04-16
A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti… Recruiting

2024-513053-69-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED) Recruiting

2024-515252-20-00 Myelofibrosis (MF) unresponsive to JAK inhibitors 9 2025-03-14
“A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive br… Recruiting

2024-519514-31-00 metastatic triple-negative PD-L1 positive breast cancer 4 2025-01-31
The use of Landiolol in mitral valve sUrgery: a raNdomized, controlled, double-blind triAl. (LUNA) Recruiting

2024-515934-34-00 Low-cardiac output syndrome (LCOS) 6 2025-01-28
Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th… Recruiting

2024-516842-21-00 Recurrent ovarian cancer 5 2025-01-09
A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type… Recruiting

2024-519481-44-00 colorectal metastatic cancer 4 2025-01-08
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting

2024-513009-30-00 Moderate to Severe Crohn’s Disease 4 2024-11-21
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch… Recruiting

2024-516782-36-00 metastatic or recurrent endometrial or ovarian carcinos 4 2024-10-15
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting

2024-511309-47-00 moderate thrombocytopenia 4 2024-07-17
N-PLUS Recruiting

2022-502559-69-01 advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 201 4 2024-07-04
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i… Recruiting

2023-508204-38-00 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) 5 2024-07-02
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can… Recruiting

2023-507914-28-00 Platinum-resistant, high-grade serous ovarian cancer (O 10 2024-06-19
Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting

2023-505929-14-00 Systemic Lupus Erythematosus 5 2024-05-21
Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Recruiting

2023-504865-21-00 Essential Thrombocythemia patients who have an inadequa 5 2024-04-15
A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting

2023-504374-38-00 Locally advanced cervical cancer 5 2024-04-12
Akynzeo as antiemetic treatment in patients with endometrial cancer treated with taxane - platinum combination chemotherapy. NOEME study. Recruiting

2023-504150-35-00 Endometrial cancer 6 2024-02-21
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31